Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Other financing activities (2021 - 2025)

InMed Pharmaceuticals (INM) has 5 years of Other financing activities data on record, last reported at $137178.0 in Q3 2025.

  • For Q3 2025, Other financing activities fell 28.49% year-over-year to $137178.0; the TTM value through Dec 2025 reached $386634.0, up 40.77%, while the annual FY2025 figure was $883978.0, 57.25% up from the prior year.
  • Other financing activities reached $137178.0 in Q3 2025 per INM's latest filing, up from $57632.0 in the prior quarter.
  • Across five years, Other financing activities topped out at $1.1 million in Q3 2021 and bottomed at $25191.0 in Q3 2023.
  • Average Other financing activities over 5 years is $351639.8, with a median of $185471.0 recorded in 2021.
  • Peak YoY movement for Other financing activities: plummeted 95.59% in 2023, then soared 661.48% in 2024.
  • A 5-year view of Other financing activities shows it stood at $179118.0 in 2021, then surged by 282.23% to $684650.0 in 2022, then crashed by 96.32% to $25191.0 in 2023, then soared by 128.78% to $57632.0 in 2024, then surged by 138.02% to $137178.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Other financing activities were $137178.0 in Q3 2025, $57632.0 in Q4 2024, and $191824.0 in Q3 2024.